Celltrion Healthcare Hungary Kft.
17 products tracked · names used in filings: Celltrion Healthcare Hungary Kft.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 08 May 2026🇪🇺 Application withdrawn (EU)
Veblocema (infliximab): EU application withdrawn
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Veblocema infliximab | Application withdrawn | |
| 🇪🇺 | Qoyvolma ustekinumab | Withdrawn | 2025-06-02 |
| 🇪🇺 | Avtozma tocilizumab | Authorised | 2025-02-14 |
| 🇪🇺 | Osenvelt denosumab | Authorised | 2025-02-14 |
| 🇪🇺 | Stoboclo denosumab | Authorised | 2025-02-14 |
| 🇪🇺 | Eydenzelt aflibercept | Authorised | 2025-02-12 |
| 🇪🇺 | Steqeyma ustekinumab | Authorised | 2024-08-22 |
| 🇪🇺 | Omlyclo omalizumab | Authorised | 2024-05-16 |
| 🇪🇺 | Vegzelma bevacizumab | Authorised | 2022-08-17 |
| 🇪🇺 | Regkirona regdanvimab | Withdrawn | 2021-11-12 |
| 🇪🇺 | Yuflyma adalimumab | Authorised | 2021-02-11 |
| 🇪🇺 | Herzuma trastuzumab | Authorised | 2018-02-09 |
| 🇪🇺 | Rituzena (previously Tuxella) rituximab | Withdrawn | 2017-07-13 |
| 🇪🇺 | Blitzima rituximab | Authorised | 2017-07-13 |
| 🇪🇺 | Ritemvia rituximab | Withdrawn | 2017-07-13 |
| 🇪🇺 | Truxima rituximab | Authorised | 2017-02-17 |
| 🇪🇺 | Remsima infliximab | Authorised | 2013-09-10 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.